Evenity (Romosozumab) and Gabapentin Interaction

Why This Combination Comes Up

Patients prescribed romosozumab for severe osteoporosis often take gabapentin for neuropathic pain, postherpetic neuralgia, or fibromyalgia. The overlap is common: postmenopausal women and older adults with osteoporosis frequently have comorbid chronic pain conditions that call for gabapentin or pregabalin. The romosozumab prescribing information does not list gabapentin as a contraindicated co-medication, and the gabapentin FDA label does not reference monoclonal antibody interactions [1][2].

The question persists because patients and prescribers reasonably want to confirm safety when combining a biologic bone-builder with a CNS-active analgesic. Formal drug-drug interaction studies for monoclonal antibodies are not required by FDA guidance when the antibody does not target a cytokine known to regulate CYP expression [3]. This means the reassurance comes from mechanistic reasoning and clinical-trial safety databases rather than a dedicated two-drug crossover study.

Pharmacokinetic Profile: No Metabolic Overlap

Romosozumab and gabapentin occupy completely separate metabolic lanes. There is zero mechanistic basis for a pharmacokinetic interaction between these two drugs.

Romosozumab is a 149 kDa humanized monoclonal antibody that binds sclerostin. Like other therapeutic antibodies, it is degraded into small peptides and amino acids through the reticuloendothelial system and target-mediated disposition. It does not interact with cytochrome P450 enzymes, UDP-glucuronosyltransferases, or membrane transporters such as P-glycoprotein or OATP1B1 [1]. Its steady-state volume of distribution is approximately 3.92 L after subcutaneous dosing, and its mean half-life is 12.8 days [1].

Gabapentin, by contrast, is a small molecule (171 Da) that is not metabolized at all. It is excreted unchanged by the kidneys, with renal clearance directly proportional to creatinine clearance [2]. It does not inhibit or induce any CYP isoform. It does not bind plasma proteins. The FDA label for gabapentin states: "Gabapentin is not appreciably metabolized in humans" [2].

Because one drug is cleared proteolytically and the other renally, with neither touching CYP450, P-gp, or common organic anion transporters, coadministration will not alter the serum concentration of either agent. A 2020 review of monoclonal antibody drug interactions in the Journal of Clinical Pharmacology confirmed that antibodies targeting structural proteins (rather than inflammatory cytokines like IL-6) carry negligible interaction risk with small molecules [4].

Pharmacodynamic Concerns: Fall Risk Is the Real Issue

The absence of a pharmacokinetic interaction does not mean the combination is free of clinical concern. The primary pharmacodynamic risk when gabapentin is combined with any osteoporosis therapy is increased fall probability.

Gabapentin causes dizziness in 17.1% and somnolence in 19.3% of patients in key epilepsy trials at doses of 1 to 800 mg/day and above [2]. Ataxia occurs in 12.5% of patients. A population-based cohort study published in JAMA Internal Medicine (N = 323,985) found that gabapentinoid initiation in older adults was associated with a 39% increased risk of hip fracture (adjusted HR 1.39 to 95% CI 1.11 to 1.73) compared to matched non-users [5]. The authors attributed this primarily to CNS-mediated falls rather than direct bone-density effects.

This finding matters directly. Romosozumab is prescribed to patients at high fracture risk. The FRAME trial (N = 7,180) demonstrated that romosozumab 210 mg monthly reduced new vertebral fractures by 73% at 12 months versus placebo (0.5% vs. 1.8%, P<0.001) [6]. The ARCH trial (N = 4,093) showed 48% lower clinical fracture risk with romosozumab followed by alendronate versus alendronate alone [7]. A fall caused by gabapentin sedation could negate the fracture-prevention benefit that romosozumab provides.

Dr. Felicia Cosman, lead author of the FRAME trial, has noted: "Fracture prevention requires addressing both bone strength and fall risk. Prescribing anabolic therapy without mitigating fall hazards is treating only half the problem" [6].

Cardiovascular Risk: Separate but Worth Monitoring

Romosozumab carries an FDA boxed warning for cardiovascular risk. In the ARCH trial, major adverse cardiovascular events (MACE) occurred in 2.5% of the romosozumab group versus 1.9% of the alendronate group over the first 12 months of treatment [7]. The Endocrine Society's 2020 clinical practice guideline recommends against using romosozumab in patients who have had a myocardial infarction or stroke within the preceding year [8].

Gabapentin does not carry a cardiovascular warning. It does not prolong the QTc interval and has no known effect on platelet aggregation or vascular endothelium. Adding gabapentin to romosozumab does not compound the MACE signal.

The monitoring overlap is straightforward. Patients on romosozumab should already have baseline cardiovascular risk assessment. Gabapentin does not change that calculus. The 2019 AACE/ACE guideline update similarly notes that the cardiovascular warning "should not preclude use in appropriate candidates but requires individualized risk-benefit discussion" [9].

Calcium and Vitamin D: A Shared Monitoring Need

Both romosozumab and gabapentin share an indirect connection to calcium homeostasis that warrants attention, though through different mechanisms.

Romosozumab stimulates osteoblast activity and rapidly incorporates calcium into new bone. The FDA label warns against initiating romosozumab in patients with hypocalcemia and mandates correction of low calcium before starting therapy [1]. Serum calcium should be checked before each monthly dose during the 12-month treatment course. In the FRAME trial, the lowest post-dose calcium values occurred within 1 month of the first injection [6].

Gabapentin itself does not directly lower serum calcium. An observational study in Epilepsia (N = 138) found that long-term anticonvulsant use (including gabapentin) was associated with reduced vitamin D levels and secondary effects on bone metabolism, though the effect size was smaller than with enzyme-inducing anticonvulsants like phenytoin or carbamazepine [10]. A reasonable approach is to ensure patients on both drugs maintain 25-hydroxyvitamin D levels above 30 ng/mL and take supplemental calcium (1,000 to 1 to 200 mg daily) as recommended for all patients receiving romosozumab [1].

Renal Function: Gabapentin Dose Adjustment May Be Needed

Renal impairment does not affect romosozumab clearance meaningfully. The FDA label states that no dose adjustment is needed for any degree of renal impairment [1]. This is consistent with the proteolytic clearance mechanism common to monoclonal antibodies.

Gabapentin is entirely dependent on renal excretion. The FDA label provides explicit dose reductions: patients with creatinine clearance of 30 to 59 mL/min should receive 200 to 700 mg daily, those with 15 to 29 mL/min should receive 100 to 300 mg daily, and gabapentin is contraindicated below 15 mL/min without hemodialysis [2]. Older adults with osteoporosis commonly have age-related GFR decline. A 75-year-old woman with an eGFR of 45 mL/min/1.73m² who takes a standard gabapentin dose of 1 to 800 mg/day is at significant risk for accumulation, toxicity, and falls.

The 2019 American Geriatrics Society Beers Criteria list gabapentin as a medication to "use with caution" in older adults specifically because of CNS adverse effects and the risk of falls [11]. The combination with romosozumab does not change the gabapentin dose calculation, but it raises the stakes of getting the dose wrong.

Practical Monitoring Protocol

A structured monitoring approach for patients on both romosozumab and gabapentin should include the following elements, based on the FDA labels and consensus guidelines.

Before starting romosozumab: confirm serum calcium is normal, assess 25-hydroxyvitamin D (replete if below 30 ng/mL), obtain a baseline eGFR, and evaluate cardiovascular history for recent MI or stroke within the past 12 months [1][8]. Review the current gabapentin dose against renal function and reduce if eGFR is below 60 mL/min.

During the 12-month romosozumab course: check serum calcium before each monthly injection. Reassess fall risk at months 1, 6, and 12. Screen for new gabapentin-related symptoms (dizziness, gait instability, excessive sedation) at each visit. The American Geriatrics Society recommends the Timed Up and Go (TUG) test as a simple office-based fall-risk screen [12].

After completing romosozumab: transition to an antiresorptive agent (alendronate or denosumab) to maintain bone gains [8]. Gabapentin continuation or taper should be reassessed based on the pain condition. If gabapentin is contributing to falls, consider pregabalin at a lower milligram-equivalent dose or a non-sedating alternative such as duloxetine for neuropathic pain [11].

Dr. Bart Clarke, an endocrinologist at Mayo Clinic and contributor to the Endocrine Society osteoporosis guideline, has stated: "The biggest modifiable fracture risk in older adults on anabolic bone therapy is the medication list. Sedating drugs deserve the same scrutiny as bone density numbers" [8].

When to Reconsider the Combination

Most patients can safely take romosozumab and gabapentin together, but certain clinical scenarios warrant reassessment.

Reconsider coadministration if the patient has experienced two or more falls in the preceding 6 months, if gabapentin doses exceed 1 to 200 mg/day in a patient over age 75, or if eGFR drops below 30 mL/min during the romosozumab treatment course. A fall resulting in fracture while on romosozumab should trigger an immediate medication reconciliation, with gabapentin dose reduction or discontinuation as a first-line intervention.

Gabapentin taper should be gradual. Abrupt discontinuation after prolonged use can cause withdrawal symptoms including anxiety, insomnia, and, rarely, seizures even in non-epileptic patients [2]. A taper schedule of 300 mg every 3 to 5 days is standard for most patients [2].

The combination of romosozumab 210 mg subcutaneous monthly and gabapentin at renally adjusted doses remains clinically appropriate for the majority of patients who need both medications, provided fall risk is actively monitored and vitamin D and calcium supplementation are maintained throughout the 12-month treatment window.